Table 2. Summary of Quality Assessments and Findings for Primary and Secondary Outcomes.

Outcomes	Quality Assessment							Summary of Findings
								Events, No./Total No. (%)		Odds Ratio (95% CI)	Control Risk, Events per 1000 Persons	Risk Difference, Increase per 1000 (95% CI)	Quality
	Studies, No.	Serious Limitations	Serious Inconsistency		Serious Indirectness	Serious Imprecision	Publication Bias Detected	NOAC	Aspirin
Primary Outcome
Intracranial hemorrhage
Rivaroxaban vs aspirin
15-20 mg daily	2	No		No	No	Yes	No	23/4716 (0.5)	7/4735 (0.1)	3.31 (1.42-7.72)	1	3 (1-10)	Moderate
10 mg daily	3	No		No	No	Yes	No	50/12 718 (0.4)	35/12 761 (0.3)	1.43 (0.93-2.21)	3	NS	Moderate
Apixaban vs Aspirin	1	No		No	No	Yes	No	11/2808 (0.4)	13/2791 (0.5)	0.84 (0.38-1.88)	5	NS	Moderate
Secondary Outcomes
Fatal bleeding
Rivaroxaban vs aspirin
15-20 mg Daily	2	No		No	No	Yes	No	36/4716 (0.8)	15/4735 (0.3)	2.37 (1.3-4.29)	3	4 (1-10)	Moderate
10 mg Daily	3	No		No	No	Yes	No	19/12 718 (0.1)	13/12 761 (0.1)	1.47 (0.72-2.97)	1	NS	Moderate
Apixaban vs aspirin	1	No		No	No	Yes	No	4/2808 (0.1)	6/2791 (0.2)	0.66 (0.19-2.35)	2	NS	Moderate
Major bleeding
Rivaroxaban vs aspirin
15-20 mg Daily	2	No		No	No	Yes	No	68/4716 (1.4)	26/4735 (0.5)	2.64 (1.68-4.16)	5	9 (4-17)	Moderate
10 mg Daily	3	No		No	No	No	No	221/12 761 (1.7)	339/12 718 (2.7)	1.56 (1.31-1.85)	17	9 (5-14)	High
Apixaban vs aspirin	1	No		No	No	Yes	No	44/2808 (1.6)	39/2791 (1.4)	1.12 (0.73-1.73)	14	NS	Moderate

Abbreviations: NOACs, non–vitamin K antagonist oral anticoagulants; NS, not significant.